Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A First-in-Human Phase 1/2 Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, Administered as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DSP-0509 (Primary) ; Pembrolizumab (Primary)
  • Indications Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Boston Biomedical

    • Most Recent Events

    • 08 Nov 2019 According to a Boston Biomedical media release, background information from the study will be presented at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting 2019.
    • 30 Sep 2019 Phase changed from I to I/II, Number of arms changed from 1 to 4, DSP-0509 will be given in combination of pembrolizumab and Planned number of patients changed from 44 to 106.
    • 13 Sep 2018 According to a Boston Biomedical media release, first patient has been dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top